The Cannabis Investing Podcast

Brad Thomas, who runs iREIT on Alpha, breaks down why cannabis REITs are an income play and a growth story. Lack of federal legalization affords cannabis REITs a strong opportunity as real estate is a big part of the industry. We discuss the value of licenses, leases, good and bad tenants. Brad's bullishness on Innovative Industrial Properties (IIPR), as well as NewLake Capital (NLCP), AFC Gamma (AFCG) and Power REIT (PW).

Catching up on the cannabis industry, we revisit some of our most salient analysis of the past 6 months. Jon DeCourcey covers upcoming tailwinds; Jason Powers and Julian Lin talk valuations and compare undervalued tech to cannabis and Nick Gastevich discusses returning to former growth rates as more states come online.

Ted Waller joins us again to discuss staying bullish but getting more realistic about the cannabis industry. Limited growth rates, margin compression and the need to keep our emotions out of investing. Buying special situations and what stocks are more concerning.

Julian Lin, founder of Cannabis Growth Investor, returns to discuss two of his favorite cannabis plays - a REIT and an MSO. Cannabis investing philosophy (valuations should drive capital allocations). Net leases, cap rates and how legislation may affect bullish thesis. Smart acquisitions, management compensation, inside ownership and understanding high debt.

With Ascend Wellness - and perhaps other MSOs - set to sue the US government, we think it's a good time to hear directly from cannabis executives to get their thoughts on the industry. We hear from TerrAscend 's Jason Wild, Ascend Wellness' Abner Kurtin, MariMed's Bob Fireman and Weedmaps' Chris Beals. As we hit mid-year, we hope this brings you more clarity into understanding the sector!

Capital is disappearing in the cannabis industry. Mike Regan and Colin Ferrian return and we discuss what investors need to understand about valuations (it's not just like tech). Grading California's main players, consumption patterns, price erosion. EBIDA over EBITDA. For a real transparent take on California trends, listen to Scotts Miracle-Gro conference call every quarter. Cyclical trends amidst secular growth and Colin turns the tables on me!

Dr. Robin Goldstein and Professor Daniel Sumner wrote Can Legal Weed Win?: The Blunt Realities of Cannabis Economics, an objective take on understanding the long-term economics of legal and illicit cannabis. Competition between legal and illicit market - not clear who wins. What types of policies will help legal weed win, learning from other commodity markets and why having a cash cushion is essential. The benefits of being a craft brand and why regional identity is key.

Patience, more institutional capital and more catalysts, but mostly we need patience as we wait for the industry to grow into a more mature sector. Matt Hawkins returns to discuss StateHouse/Harborside, the California cannabis market and the developing US landscape. Advice to retail investors and why managing cash is key. Institutional capital will come in and everyone will want in on an MSO or wanting to partner with an MSO. That's where the money is going to be made.

Michael Auerbach, Founder and Chairman of Subversive Capital and The Parent Company (OTCQX:GRAMF) first came on for our first two SPAC Weeks and returns today to update us on GRAMF and the growth that hasn't shown up the way we expected. InterCure and the Israeli market. We also discuss his new ETF PUNK, which came on the scene and shorted Meta.

Julian Lin catches us up on recent earnings volatility, valuations and how investors should be looking at the cannabis industry. Why he's a big fan of Verano but not a fan of the Cresco/Columbia Care merger. IIPR, NewLake Capital and why cannabis REITs are highly compelling.